May 2013

LLS, Valor Biotherapeutics partner to advance novel therapy

Thursday, May 30, 2013

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency,  is committing approximately $6 million to Valor Biotherapeutics, a joint venture of biotechnology companies ImmunGene and Caliber, to co-fund the completion of preclinical development, manufacturing and a phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with indolent lymphomas who do not respond to standard therapy with rituximab.

[Read More]

FDA lifts clinical hold on anthrax vaccine program

Thursday, May 30, 2013

PharmAthene, a biodefense company developing medical countermeasures against biological and chemical threats, said the FDA has lifted the clinical hold previously placed on a proposed phase II study of SparVax, a next generation recombinant anthrax vaccine.

“Anthrax has been identified as one of the foremost potential biological threats to the nation,” said Eric I. Richman, president and CEO.  “The U.S. government’s requirement for a recombinant anthrax vaccine for the civilian Strategic National Stockpile is an important national security imperative that remains unfilled. Next-generation anthrax vaccines like SparVax, which employ modern vaccine technology, offer the potential for improved convenience, cost-effectiveness, more rapid immunity, and the ability for large scale rapid delivery.”

[Read More]

Avillion appoints Ramani Varanasi chief business officer

Thursday, May 30, 2013

Avillion, which focuses on clinical co-development of therapeutics, has expanded its leadership team, appointing Ramani Varanasi, MSc, MBA, chief business officer.

Varanasi has 18 years of biotechnology and pharmaceutical industry experience  in structuring, negotiating and executing successful strategic alliances, licensing agreements and M&A transactions, as well as in business development, management and strategic leadership.

[Read More]